BioNTech to Present Oncology Pipeline Data at AACR Meeting

TL;DR

BioNTech presenting new cancer drug data at AACR next week.

AI Summary

On April 24, 2025, BioNTech SE announced its upcoming presentation of data for several oncology pipeline assets, including mRNA cancer immunotherapies. The company will share these updates at the 2025 American Association for Cancer Research (AACR) Annual Meeting in San Diego, California.

Why It Matters

This presentation highlights BioNTech's progress in its diversified oncology pipeline, potentially signaling future drug development and market opportunities.

Risk Assessment

Risk Level: low — This filing is an announcement of data presentation, not a financial event or material change in business operations.

Key Players & Entities

• BioNTech SE (company) — Registrant
• April 24, 2025 (date) — Announcement date
• 2025 American Association for Cancer Research (AACR) Annual Meeting (event) — Presentation venue
• San Diego, California (location) — Presentation location

FAQ

From the Filing

0001776985-25-000021.txt : 20250424 0001776985-25-000021.hdr.sgml : 20250424 20250424075423 ACCESSION NUMBER: 0001776985-25-000021 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250424 FILED AS OF DATE: 20250424 DATE AS OF CHANGE: 20250424 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 25863608 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kaacrcurtainraiserpr.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF APRIL 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On April 24, 2025, BioNTech SE announced that it will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The press release is attached hereto as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: April 24, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 EX-99.1 2 a99_1250424xbntxxaacrcurta.htm EX-99.1 Document Exhibit 99.1 BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025 MAINZ, Germany, April 24, 2025  -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech’s advanced priority oncology programs as well as the execution of the Company’s combination strategy in oncology, with first data to be presented for the combination of the PD-L1xVEGF-A bispecific antibody candidate BNT327 1 plus antibody-drug conjugates (“ADCs”). “We believe that the future standard of care for the treatment of advanced cancers will be combinations with novel immuno-oncology backbones,”